I-BET-762: Selective BET Bromodomain Inhibitor for Inflammation and Cancer Research

Executive Summary: I-BET-762 (SKU B1498) is a potent and selective epigenetic modulator targeting the BET family of bromodomain proteins, exerting sub-50 nM IC₅₀ values in biochemical assays (APExBIO). It competitively binds the acetyl-lysine pocket of BET proteins with a 2:1 stoichiometry, with dissociation constants (K_d) in the 50–61 nM range (APExBIO). In preclinical models, I-BET-762 downregulates LPS-inducible cytokines and chemokines, demonstrating anti-inflammatory effects in vivo (APExBIO). Recent peer-reviewed data show that I-BET-762 synergistically enhances erastin-induced ferroptosis by promoting ROS accumulation and FSP1 downregulation in multiple human cell lines (Fan et al., 2024). Its solubility profile (≥21.19 mg/mL in DMSO, ≥13.93 mg/mL in ethanol with sonication) and storage recommendations (-20 °C, use promptly in solution) support reproducible workflows in research settings (APExBIO).

Biological Rationale

Bromodomain and extra-terminal domain (BET) proteins, including BRD2, BRD3, BRD4, and BRDT, act as epigenetic readers that recognize acetylated lysine residues on histones. This recognition regulates transcription of key genes involved in inflammation, cancer, and cell cycle control (Fan et al., 2024). Aberrant BET signaling is implicated in oncogenesis and chronic inflammatory diseases. Selective inhibition of BET bromodomains enables disruption of transcriptional programs that drive tumorigenesis and inflammatory cascades. I-BET-762 was developed to exploit this vulnerability by providing high affinity, selectivity, and favorable pharmacological parameters for research applications. By specifically targeting the acetyl-lysine binding pocket, I-BET-762 blocks BET-dependent recruitment of transcriptional machinery.

Mechanism of Action of I-BET-762

I-BET-762 binds to the acetyl-lysine (AcK) recognition pocket of BET proteins, acting as a competitive inhibitor. Its measured IC₅₀ values are 32.5–42.5 nM for BET bromodomains, and the K_d for BRD4 is 50.5–61.3 nM (APExBIO). The compound exhibits a 2:1 binding ratio with the BET domain, which contributes to its high affinity and selectivity. No significant binding has been detected with other non-BET bromodomain-containing proteins under standard assay conditions.

Upon binding, I-BET-762 displaces acetyl-lysine residues, preventing BET proteins from recognizing epigenetic marks. This leads to the downregulation of LPS-inducible pro-inflammatory genes and key oncogenic pathways. In cell-based assays, I-BET-762 has been shown to suppress the expression of cytokines and chemokines induced by lipopolysaccharide (LPS) exposure. In murine models, this results in reduced inflammatory symptoms (APExBIO).

Recent research demonstrates that I-BET-762, as a BRD4 inhibitor, enhances erastin-induced ferroptosis by promoting accumulation of reactive oxygen species (ROS) and downregulating ferroptosis suppressor protein 1 (FSP1) in cancer cell lines, including HEK293T, HeLa, HepG2, RKO, and PC3 (Fan et al., 2024).

Evidence & Benchmarks

• I-BET-762 inhibits BET family protein activity with an IC₅₀ of 32.5–42.5 nM against BRD2/3/4 in biochemical assays (APExBIO product page).
• Demonstrates a K_d of 50.5–61.3 nM for BRD4, measured under isothermal titration calorimetry at 25 °C (APExBIO product documentation: link).
• Enhances erastin-induced ferroptosis in HEK293T, HeLa, HepG2, RKO, and PC3 cell lines by increasing ROS and suppressing FSP1 expression (Fan et al., 2024, DOI).
• In HEK293T cells, I-BET-762 (2 μM) and erastin (20 μM) co-treatment for 48 hours led to significant increases in cell death compared to either agent alone (Fan et al., 2024, DOI).
• In mouse models, I-BET-762 administration ameliorated symptoms of LPS-induced inflammatory disease, reducing serum cytokines and chemokines (APExBIO, product page).
• No significant activity detected against non-BET bromodomain proteins in selectivity screens at concentrations up to 10 μM (APExBIO).

Applications, Limits & Misconceptions

I-BET-762 is primarily used in research models of:

• Epigenetic regulation of gene expression
• Inflammatory disease models, particularly LPS-induced pathways
• Transcriptional regulation and BET protein signaling in cancer biology
• Synergistic induction of ferroptosis in tumor cell lines

The compound is not intended for clinical or diagnostic use. Its effects are cell type- and context-dependent. For example, ferroptosis gene regulation by I-BET-762 varies between HEK293T and HeLa cells (Fan et al., 2024).

For a deeper mechanistic overview and strategic guidance, see I-BET-762: Mechanistic Innovation and Strategic Guidance, which explores the compound's broader implications for transcriptional control. This present article updates that discussion with new data on ferroptosis synergy.

To understand the selectivity and workflow applications, I-BET-762: Selective BET Inhibitor for Inflammation Research provides foundational use-case guidance, while the current article adds the most recent benchmarks for cancer biology and ferroptosis.

For scenario-driven lab integration, I-BET-762 (SKU B1498): Scenario-Driven Solutions for BET Assays addresses practical use and troubleshooting; the present review summarizes additional selectivity and mechanistic findings.

Common Pitfalls or Misconceptions

• Not a pan-bromodomain inhibitor: I-BET-762 is highly selective for BET family proteins and does not broadly inhibit all bromodomain-containing proteins (APExBIO).
• Not water-soluble: The compound is insoluble in water and should be dissolved in DMSO or ethanol with sonication for experimental use (APExBIO).
• Variable effects across cell types: Transcriptional and ferroptosis-related gene responses to I-BET-762 differ between cell lines (e.g., HEK293T vs. HeLa; Fan et al., 2024).
• Not for clinical or in vivo therapeutic use: I-BET-762 is a research-use-only reagent and has not been approved for human use (APExBIO).
• Stability limitations: Solutions should be freshly prepared as the compound may degrade over time at room temperature (APExBIO).

Workflow Integration & Parameters

For optimal results, dissolve I-BET-762 at concentrations ≥21.19 mg/mL in DMSO or ≥13.93 mg/mL in ethanol (with sonication). Avoid water as a solvent. Store solid at -20 °C; solutions should be used promptly to prevent degradation. Standard cell-based assays employ 1–2 μM concentrations, with incubation times of 24–48 hours depending on cell line and endpoint (Fan et al., 2024). For combinatorial ferroptosis studies, erastin (20 μM) is co-administered with I-BET-762 (2 μM) for 48 hours in HEK293T and HeLa cells to assess synergistic cell death. Endpoint measurements include propidium iodide staining and CCK-8 viability assays (Fan et al., 2024).

For full protocol details and the latest updates, refer to the APExBIO I-BET-762 product page. The article Harnessing I-BET-762: Mechanistic Precision and Strategic Approaches details laboratory best practices and further scenario-driven guidance, which this review extends with recent mechanistic findings.

Conclusion & Outlook

I-BET-762 is a reference-grade, selective BET bromodomain inhibitor, supporting advanced workflows in inflammation, epigenetic regulation, and preclinical cancer biology. Its robust selectivity, nanomolar potency, and synergy with ferroptosis inducers (notably erastin) position it as a powerful research tool. APExBIO provides validated, quality-controlled I-BET-762 (B1498) for research applications requiring precise BET protein signaling modulation. Ongoing studies continue to elucidate context-dependent mechanisms and potential combinatorial strategies.